RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL

被引：0
|
作者：
Farhat, Fadi [6 ]
Martin, Miguel [7 ]
Campone, Mario [8 ]
Bachelot, Thomas [1 ]
Neven, Patrick [12 ]
Martinez Rodriguez, Jorge Luis [3 ,4 ]
Yusof, Mastura Md [11 ]
Papazisis, Konstantinos [5 ]
Ferreira, Ana [2 ]
Ankrah, Nii [9 ]
Wu, Jiwen [9 ]
Zhou, Katie [9 ]
De laurentiis, Michelino [10 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] CUF Porto Hosp, Inst CUF Oncol, Porto, Portugal
[3] Escuela Nacl Med, Monterrey, Nuevo Leon, Mexico
[4] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico
[5] Euromed Gen Clin, Dept Oncol, Thessaloniki, Greece
[6] Hammoud Hosp UMC, Hematol Oncol Div, Saida, Lebanon
[7] Hosp Gregorio Maranon, Dept Oncol, Madrid, Spain
[8] Inst Canc Res Western France ICO, Lyon, France
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Natl Canc Inst, Fdn Pascale, Naples, Italy
[11] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[12] Univ Hosp Leuven UZ Leuven, Dept Obstet Gynecol, Leuven, Belgium
来源：
BREAST | 2019年 / 48卷
关键词：
D O I：
10.1016/S0960-9776(19)30676-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO67
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
    De Laurentiis, Michelino
    Campone, Mario
    Alba Conejo, Emilio
    Tanner, Minna
    Egle, Daniel
    Papai, Zsuzsanna
    Prat Aparicio, Aleix
    Dent, Susan
    Warner, Ellen
    Ankrah, Nii
    Wu, Jiwen
    Zhou, Katie
    Borstnar, Simona
    BREAST, 2019, 48 : S46 - S47
  • [2] Ribociclib (RIBO) plus letrozole (LET) in older patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial
    Ring, A.
    Borstnar, S.
    Ferreira, A.
    Azim, H. A.
    Cottu, P.
    Lu, J.
    Martin, M.
    Zamagni, C.
    Beck, J. T.
    Zhou, K.
    Wu, J.
    Menon, L.
    De laurentiis, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
    Campone, M.
    De laurentiis, M.
    Zamagni, C.
    Kudryavcev, I.
    Agterof, M.
    Brown-Glaberman, U.
    Palacova, M.
    Chatterjee, S.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Martin, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Prat, Aleix
    Chia, Stephen
    Jerusalem, Guy
    Rajappa, Senthil
    Timcheva, Constanta
    Zhukova, Lyudmila
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    De Laurentiis, Michelino
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Cottu, Paul
    De Laurentiis, Michelino
    Marchetti, Paolo
    Coltelli, Luigi
    Califaretti, Nadia
    Debled, Marc
    Patil, Shekar
    Evron, Ella
    Duhoux, Francois
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Bofill, Javier Salvador
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Ribociclib (RIB) plus letrozole (LET) in Asian patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2L-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Chatterjee, S.
    Yusof, M. Md
    Dejthevaporn, T.
    Chung, W-P.
    Galvez, C. G.
    Sunpaweravong, P.
    Cheng, A.
    Abesamis-Tiambeng, M. L. T.
    Michelle, S. O. Y.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Azim, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1260 - S1261
  • [7] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Abdel-Razeq, H.
    Cottu, P. H.
    Ring, A.
    De laurentiis, M.
    Lu, J.
    Azim, H. A.
    Zamagni, C.
    Zhou, K.
    Wu, J.
    Menon, L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Razeq, Hikmat Abdel
    Cottu, Paul
    Ring, Alistair
    De laurentiis, Michelino
    Lu, Janice
    Azim, Hamdy
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Zamagni, C.
    Campone, M.
    Kudryavcev, I.
    Brown-Glaberman, U.
    Cottu, P. H.
    Ring, A.
    Lu, J.
    Martin, M.
    De laurentiis, M.
    Zhou, K.
    Wu, J.
    Menon, L.
    Azim, H. A.
    ANNALS OF ONCOLOGY, 2018, 29
12345